GSK250103C40000
- 0.00
- 0.000.00%
GlaxoSmithKline Newsroom
GSK, Pfizer RSV Shots to Get Warning of Rare Neurological Disorder
Express News | The USA Food and Drug Administration (FDA): GlaxoSmithKline and Pfizer must issue warnings regarding their respiratory syncytial virus (RSV) vaccines. The RSV vaccines from these two companies may increase the risk of rare neurological side effects.
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
GSK's Bone Cancer Treatment Receives Breakthrough Designation From US FDA
GSK's Experimental Cancer Drug Wins Receives Support From US Regulator | LSE:GSK, NYSE:GSK
Bernstein Remains a Buy on GlaxoSmithKline (GSK)
Bird Flu Claims First U.S. Life in Louisiana
'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Why Is GSK Plc (NYSE:GSK) Among the Best FTSE Dividend Stocks to Buy Now?
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
GlaxoSmithKline (GSK.US) has another new indication application for the Class 1 new drug Dermoracimab accepted.
Depemokimab (GSK3511294) is a long-acting IL-5 antagonist that has an extended half-life.
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
Express News | GlaxoSmithKline: New Kleran has been approved in China for the treatment of adult chronic sinusitis with nasal polyps.
GSK Gets Approval in China for Nucala for Rhinosinusitis
GSK Wins Chinese Nod for Nucala as Chronic Rhinosinusitis Treatment